These studies collectively highlight the significant role of exosome-mediated purine metabolic disorders and lysosomal dysfunction in the progression of gout, laying the theoretical foundation for CTSD and HPRT1 as biomarkers for diagnosing gouty arthritis clinically and developing therapeutic strategies targeting exosomes. This evidence concerns the gene CTSD and Disorder of purine metabolism.